07 October 2014
Generics Announces Positive Phase 3 Results for APD421 in PONV
30 October 2013
Phase 2 Study Initiated With APD403 In CINV15 October 2013
Generics Announces Positive Phase 2 Results With APD515 For Xerostomia In Advanced Cancer17 September 2013
Pivotal Phase 3 Studies Initiated With APD421 in PONV01 October 2012
Generics Announces Positive Results From Phase 2a Nausea & Vomiting Study In Cancer Patients31 March 2011
Generics Closes $10 Million Investment Round07 February 2011
Phase 1 Clinical Trial Completed With APD515 For Xerostomia06 January 2011
Generics Starts Clinical Trial With APD515 For Xerostomia06 January 2011
New Website Launched06 September 2010
Generics to Progress Two Projects for Nausea & Vomiting and Xerostomia into Development14 December 2009
Generics Completes Phase II Study with APD405 in Post-Operative Nausea & Vomiting (PONV)08 June 2009
Generics Initiates Phase II Study with APD405 in Post-Operative Nausea & Vomiting (PONV)05 February 2009
Ian Kent Appointed as Chairman04 March 2008
Chief Medical Officer Appointed04 March 2008
Gilde Healthcare Investment in Generics